Trial Profile
Phase II study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Dec 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 30 Dec 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Jul 2009 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University record NU-HOG08L1).